Full-Time
Posted on 10/30/2025
Stem cell therapies from deceased donors
No salary listed
Company Does Not Provide H1B Sponsorship
Indianapolis, IN, USA
In Person
| , , , , |
Ossium Health develops cell therapies using stem cells from deceased donors to treat blood diseases and immune disorders, reduce organ transplant rejection, and address orthopedic conditions. Therapies are created through research, clinical trials, and partnerships, and distributed via collaborations and licensing to bring proprietary products to patients. The company differentiates itself by leveraging deceased-donor stem cells and close ties with organ procurement networks, building a portfolio across hematology, immunology, transplantation, and orthopedics. The goal is to make effective donor-derived cell therapies more accessible to improve health, vitality, and longevity.
Company Size
51-200
Company Stage
Series C
Total Funding
$134.9M
Headquarters
San Francisco, California
Founded
2016
Help us improve and share your feedback! Did you find this helpful?
Medical, dental and vision coverage
401(k) Company Match
Stock Options
Unlimited Paid Time Off
Employer paid life insurance and long term disability
Gym membership/recreational sports reimbursements
Ossium Health's Indianapolis facility reflects the rise of life sciences real estate. April 20, 2026 Indianapolis is home to Ossium Health, a biotech company which operates the world's first bone marrow bank for the treatment of diseases of the blood and immune systems. Bone marrow banking is the process of collecting, processing, and storing bone marrow stem cells so they are available for medical treatment when needed, rather than relying on live donors at the time of illness. Govenor Mike Braun toured Ossium's nearly 34,000 SF production facility at 5742 W 74th Street last week after recently announcing $1B in incentives for life sciences. The visit highlighted Ossium's innovative work and emphasized Indianapolis' potential for becoming the Silicon Valley for life sciences. The building includes multiple cleanrooms, research and development laboratories, bulk storage areas, and office space for a growing team of scientists, production specialists, and quality personnel. This type of buildout underscores a key trend in industrial real estate, which is that life sciences users require highly customized spaces that support strict regulatory standards, advanced infrastructure, and long-term scalability. Facilities like Ossium's push far beyond traditional warehouse or flex space, blending elements of industrial, lab, and office environments into a single, specialized footprint. Indianapolis continues to strengthen its position as a growing hub for life sciences and advanced manufacturing, and Weston Inc. is pleased to have Ossium as a tenant. Ask Weston Inc. any questions. Its representatives are available to help answer your questions.
Forbes selects Ossium as one of America's Best Startup Employers. For the second time in three years, Ossium Health has been named to Forbes' list of America's Best Startup Employers. This annual list highlights a select group of U.S. startups that demonstrate excellence in employee satisfaction, employer reputation, and organizational growth - criteria that reflect not only business performance, but the strength of a company's culture and its ability to attract and retain exceptional talent. At Ossium, its work is driven by a singular mission: to improve the health, vitality, and longevity of human beings through bioengineering. Achieving this mission requires bringing together individuals who are deeply committed to scientific innovation and motivated by the opportunity to make a meaningful impact on patients facing serious and life-threatening conditions. Being recognized by Forbes underscores the environment ossiumhealth.com has built: one where talented individuals can do their best work in pursuit of transformative medical advances. Its team's dedication extends beyond day-to-day responsibilities. It is reflected in the care with which ossiumhealth.com develop and deliver novel cell-based therapies, the rigor of its clinical and research programs, and the shared sense of purpose that unites its organization. ossiumhealth.com believe that fostering a mission-driven, collaborative, and supportive workplace is essential to advancing breakthroughs that save lives. "This recognition is a direct reflection of our team and the culture we've built together," said Kevin Caldwell, CEO, President & Co-founder of Ossium Health. "We've assembled a group of people who are not only exceptionally talented, but deeply committed to our mission. Their passion, integrity, and persistence are what enable us to pursue ambitious goals in bioengineering and deliver meaningful impact for patients. We're honored to be recognized alongside other outstanding startups and remain focused on building an organization where people can do the most important work of their careers." Ossium is actively growing and looking for exceptional individuals to join its team. If you're motivated by the opportunity to help pioneer the future of bioengineering and make a meaningful difference for patients, ossiumhealth.com encourage you to explore open roles at ossiumhealth.com/careers. ossiumhealth.com is grateful to its entire team for their contributions and proud to be included among this year's Best Startup Employers. Join its team. At Ossium, ossiumhealth.com is always looking for talented, mission-driven people.
Ossium Health to present new clinical data from PRESERVE I study at the 2026 Tandem Meetings. January 23rd, 2026 | Business Wire SAN FRANCISCO - (BUSINESS WIRE) - Ossium Health, a clinical-stage biotechnology company pioneering off-the-shelf bone marrow therapies derived from deceased organ donors, today announced it will present new clinical data from its ongoing PRESERVE I study at the 2026 Tandem Meetings taking place on February 4-7, 2026 in Salt Lake City, UT. Ossium will deliver one oral presentation and three poster presentations highlighting clinical experience with its cryopreserved, donor-derived bone marrow platform. The featured oral presentation will showcase first-in-human clinical data from the first four patients treated in the PRESERVE I study, marking an important milestone in the advancement of off-the-shelf bone marrow transplantation. Ossium's Chief Medical Officer, Dr. Sagar Munjal, will present the study's encouraging preliminary data, which demonstrate the safety and feasibility of transplanting bone marrow derived from deceased donors. Additional poster presentations underscore key advantages of Ossium's off-the-shelf bone marrow platform, including its ability to provide immediate graft availability in urgent scenarios when a living donor becomes unavailable, as well as its potential to reduce relapse risk. Title: A First-in-Human Study of HLA-Partially to Fully Matched Allogeneic Cryopreserved Deceased Donor Bone Marrow Transplantation for Patients with Hematologic Malignancies Presenter: Sagar Munjal, MD, Chief Medical Officer & Senior Vice President, Ossium Health Presentation ID: 89 Date and Time: Saturday, Feb 7, 11:30 AM - 11:45 AM MST Location: Ballroom J Title: Demonstrating the Feasibility of Refreezing Previously Cryopreserved Bone Marrow Following Reprocessing Poster ID: 296 Date and Time: Thursday, Feb 5, 6:30 PM - 8:00 PM MST Location: Hall AB "These presentations highlight the growing clinical body of evidence supporting the feasibility, safety, and transformative potential of Ossium bone marrow," said Kevin Caldwell, CEO, Co-Founder & President of Ossium Health. "We look forward to sharing insights from PRESERVE I and related clinical experience with the transplant community at Tandem." The company will also exhibit at Booth #106, where attendees can learn more about Ossium's organ donor-derived bone marrow banking platform and clinical studies. The Tandem Meetings are jointly hosted by the American Society for Transplantation and Cellular Therapy (ASTCT) and the Center for International Blood and Marrow Transplant Research (CIBMTR) and represent one of the premier global forums for advances in hematopoietic cell transplantation and cellular therapy. About Ossium Health Ossium Health is a bioengineering company that leverages its proprietary organ donor bone marrow banking platform to develop stem cell therapies for patients with life-threatening hematologic conditions, organ transplant rejection, and musculoskeletal defects. Founded in 2016, the company is led by Kevin Caldwell, Chief Executive Officer, President and Co-Founder, and Erik Woods, Chief Science Officer, Executive Vice President and Co-Founder. Ossium Health's manufacturing facility is registered with the FDA and its laboratory is certified under the Clinical Laboratory Improvement Amendments (CLIA). For more information, please visit https://ossiumhealth.com. Follow the company on LinkedIn at https://www.linkedin.com/company/ossiumhealth/ and X at https://x.com/ossiumhealth. Jane Griffin Ossium Health, Inc. 415-513-5535 [email protected] January 23rd, 2026
ossiumhealth.com is excited to announce that Ossium will be exhibiting at the 2025 Transplantation & Cellular Therapy (Tandem) Meetings of ASTCT and CIBMTR, taking place from February 12-15 in Honolulu, Hawaii.
Ossium ranks No. 56 on Fast Company's 100 Best Workplaces for Innovators.